^
BIOMARKER:

ARID1A mutation

i
Other names: ARID1A, AT-Rich Interaction Domain 1A, SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator Of Chromatin Subfamily F Member 1, AT-Rich Interactive Domain-Containing Protein 1A, AT Rich Interactive Domain 1A (SWI-Like), ARID Domain-Containing Protein 1A, SWI/SNF Complex Protein P270, BRG1-Associated Factor 250a, SWI-Like Protein, Osa Homolog 1, SMARCF1, C1orf4, BAF250, HOSA1, OSA1, AT Rich Interactive Domain 1A (SWI- Like), Chromatin Remodeling Factor P250, BRG1-Associated Factor 250, OS
Entrez ID:
Related biomarkers:
ARID1A mutation
NSCLC
durvalumab + CP-675206
Sensitive: B - Late Trials
ARID1A mutation
NSCLC
Immunotherapy
Sensitive: B - Late Trials
ARID1A mutation
RCC
sunitinib
Sensitive: B - Late Trials
ARID1A mutation
HCC
Immunotherapy
Sensitive: C3 – Early Trials
ARID1A mutation
Cholangiocarcinoma
Immunotherapy
Sensitive: C3 – Early Trials
ARID1A mutation
Gastric Cancer
Immunotherapy
Sensitive: C3 – Early Trials
ARID1A mutation
Esophageal Adenocarcinoma
Immunotherapy
Sensitive: C3 – Early Trials
ARID1A mutation
Gastrointestinal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
ARID1A mutation
Head and Neck Cancer
Immunotherapy
Sensitive: C3 – Early Trials
ARID1A mutation
Breast Cancer
Immunotherapy
Sensitive: C3 – Early Trials
ARID1A mutation
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
ARID1A mutation
Endometrial Cancer
Immunotherapy
Sensitive: C3 – Early Trials
ARID1A mutation
Pancreatic Ductal Adenocarcinoma
Immunotherapy
Sensitive: C3 – Early Trials
ARID1A mutation
Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
ARID1A mutation
Neuroendocrine Tumor
toripalimab
Sensitive: C3 – Early Trials
ARID1A mutation
Solid Tumor
AZD6738
Sensitive: C3 – Early Trials
ARID1A mutation
CRC
cetuximab
Resistant: D – Preclinical
ARID1A mutation
Ovarian Cancer
GSK2816126
Sensitive: D – Preclinical
ARID1A mutation
Bladder Cancer
GSK2816126
Sensitive: D – Preclinical
ARID1A mutation
Gastric Cancer
EZH2 inhibitor
Sensitive: D – Preclinical